Does denosumab or alendronic acid prevent progression of aortic valve calcification in patients with calcific aortic stenosis?
Denosumab and alendronic acid do not modify the disease progression of calcific aortic stenosis.
Neither denosumab nor alendronic acid affected progression of aortic valve calcification in patients with calcific aortic stenosis. Alternative pathways and mechanisms need to be explored to identify disease-modifying therapies for the growing population of patients with this potentially fatal condition. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02132026.
Pawade et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: